Tuesday, 17 Nov 2009 | Source: The Associated Press
Shares of InterMune Inc. fell Tuesday after the biotechnology company said it would discontinue a high-dose of its experimental Hepatitis C treatment in a study because of potential liver damage.
Stock futures pointed to a modest rebound ahead of the open Monday after the Dow and the S&P 500 experienced their biggest one-day percentage drops Friday since July 2.